Drug
LY3454738
LY3454738 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 50.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 2 completed trials
Completion Rate
50%(2/4)
Active Trials
0(0%)
Results Posted
100%(2 trials)
Terminated
2(50%)
Phase Distribution
Ph phase_1
2
50%
Ph phase_2
2
50%
Phase Distribution
2
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
2(50.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Terminated(2)
Detailed Status
Terminated2
Completed2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
50.0%
Most Advanced
Phase 2
Trials by Phase
Phase 12 (50.0%)
Phase 22 (50.0%)
Trials by Status
terminated250%
completed250%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_2
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT05911841
completedphase_1
A Relative Bioavailability Study of LY3454738 in Healthy Participants
NCT06173895
terminatedphase_2
A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria
NCT04159701
completedphase_1
A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis
NCT03750643
Clinical Trials (4)
Showing 4 of 4 trials
NCT05911841Phase 2
A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT06173895Phase 1
A Relative Bioavailability Study of LY3454738 in Healthy Participants
NCT04159701Phase 2
A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria
NCT03750643Phase 1
A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4